Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial
暂无分享,去创建一个
E. Vittinghoff | J. Cauley | E. Barrett-Connor | D. Herrington | D. Grady | V. Bittner | A. Kanaya | F. Lin
[1] High blood pressure and the incidence of non-insulin dependent diabetes mellitus: Findings in A 11.5 year follow-up study in the Netherlands , 1993, European Journal of Epidemiology.
[2] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[3] B. Howard,et al. The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study. , 2002, Diabetes care.
[4] Robert Selzer,et al. Estrogen in the Prevention of Atherosclerosis , 2001, Annals of Internal Medicine.
[5] K. Schenck-Gustafsson,et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 2001, Circulation.
[6] W. Sutherland,et al. The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial. , 2001, Archives of internal medicine.
[7] T. Bush,et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. , 2001, Fertility and sterility.
[8] Jennifer Y. Liu,et al. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. , 2001, Diabetes care.
[9] J. Connell,et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. , 2001, The Journal of clinical endocrinology and metabolism.
[10] M. Savolainen,et al. Effects of peroral and transdermal oestrogen replacement therapy on glucose and insulin metabolism , 2001, Clinical Endocrinology.
[11] S. Azen,et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.
[12] K. Friday,et al. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.
[13] J. Westerbacka,et al. Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.
[14] M. Mclaren,et al. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. , 2000, Family practice.
[15] K. Maki,et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. , 2000, Archives of internal medicine.
[16] R. Troisi,et al. Hormone Replacement Therapy and Glucose Metabolism , 2000, Obstetrics and gynecology.
[17] A. Dornhorst,et al. Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. , 2000, Diabetes research and clinical practice.
[18] K. McPherson,et al. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease , 2000, The Lancet.
[19] E. Vittinghoff,et al. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.
[20] N. Wareham,et al. Hormone replacement therapy and glucose tolerance in EPIC‐Norfolk: a population‐based study , 2000, Diabetes/metabolism research and reviews.
[21] C. Stehouwer,et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[22] D. Porte. Mechanisms for Hyperglycemia in the Metabolic Syndrome: The Key Role of β‐Cell Dysfunction , 1999, Annals of the New York Academy of Sciences.
[23] C. Hayward,et al. Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. , 1999, Diabetes care.
[24] G. Riccardi,et al. Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. , 1999, Diabetes care.
[25] J Tuomilehto,et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? , 1999, Diabetes care.
[26] L. Heinemann,et al. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. , 1999, Menopause.
[27] J. Tuomilehto,et al. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). , 1999, Diabetes care.
[28] M. Espeland,et al. Effect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations , 1998, Diabetes Care.
[29] S Hulley,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[30] S B Hulley,et al. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. , 1998, Controlled clinical trials.
[31] N. Colacurci,et al. Effects of hormone replacement therapy on glucose metabolism. , 1998, Panminerva medica.
[32] E. Barrett-Connor,et al. The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. , 1997, American journal of public health.
[33] W. Duyvenvoorde,et al. Effect of 17β-Estradiol on Plasma Lipids and LDL Oxidation in Postmenopausal Women With Type II Diabetes Mellitus , 1997 .
[34] P. Björntorp,et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.
[36] A. Van der Laarse,et al. Effect of 17 beta-estradiol on plasma lipids and LDL oxidation in postmenopausal women with type II diabetes mellitus. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[37] J. Clasey,et al. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.
[38] A. O’Sullivan,et al. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. , 1995, The Journal of clinical endocrinology and metabolism.
[39] J. Stevenson,et al. THE METABOLIC AND CARDIOVASCULAR CONSEQUENCES OF HRT , 1995, The British journal of clinical practice.
[40] Susan R. Johnson,et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .
[41] Ján,et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1995, JAMA.
[42] B. Walsh,et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women , 1994, Obstetrics and gynecology.
[43] R. Lobo,et al. The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women. , 1994, Fertility and sterility.
[44] A. Folsom,et al. Association of Hormone-Replacement Therapy With Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .
[45] P. Björntorp,et al. The effects of oestrogen and progesterone on insulin sensitivity in female rats. , 1993, Acta physiologica Scandinavica.
[46] A. Folsom,et al. Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .
[47] A. Paoletti,et al. Effects of Low Doses of Transdermal 17β-Estradiol on Carbohydrate Metabolism in Postmenopausal Women , 1992 .
[48] J. Manson,et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. , 1992, Annals of epidemiology.
[49] P. Fioretti,et al. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.
[50] E. Barrett-Connor,et al. Evaluation of Fasting Plasma Glucose as Screening Test for NIDDM in Older Adults: Rancho Bernardo Study , 1991, Diabetes Care.
[51] M. Laakso,et al. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. , 1990, Arteriosclerosis.
[52] C. Bengtsson,et al. Do antihypertensive drugs precipitate diabetes? , 1984, British medical journal.
[53] L. Grant,et al. Brainstem catecholamine neurons are target sites for sex steroid hormones , 1980, Science.
[54] W. Creasman,et al. Effects of long-term estrogen replacement therapy. II. Neoplasia. , 1979, American journal of obstetrics and gynecology.
[55] E. Beckman,et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. , 1979, Obstetrics and gynecology.
[56] W. Creasman,et al. Effects of long-term estrogen replacement therapy. I. Metabolic effects. , 1979, American journal of obstetrics and gynecology.
[57] C. Kahn,et al. Alterations in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone. , 1978, Endocrinology.
[58] L. Wallentin,et al. Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. I. Glucose, insulin and human growth hormone levels during oral glucose tolerance tests. , 1977, Acta endocrinologica.
[59] M. L. Matute,et al. Sex steroid influence on hepatic gluconeogenesis and glucogen formation. , 1973, Endocrinology.
[60] W. Spellacy,et al. The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. , 1972, American journal of obstetrics and gynecology.
[61] S. Yen,et al. Effect of exogenous estrogen on carbohydrate metabolism in postmenopausal women. , 1972, American journal of obstetrics and gynecology.